These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28608143)

  • 1. Resource Utilization Among Glaucoma Patients in the UK Treated with Beta-Blocker and Non-Beta-Blocker Adjunctive Therapy: A Retrospective Cohort Analysis.
    Viswanathan A; Spera C; Mullins A; Covert D; Banhazi J; McDwyer P; Hudson E; Ferreira A
    Adv Ther; 2017 Jul; 34(7):1695-1706. PubMed ID: 28608143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucoma.
    Schmier JK; Covert DW; Lau EC
    Clin Drug Investig; 2012 Dec; 32(12):835-42. PubMed ID: 23138648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between topical β-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database.
    Kido A; Miyake M; Akagi T; Ikeda HO; Kameda T; Suda K; Hasegawa T; Hiragi S; Yoshida S; Tsujikawa A; Tamura H; Kawakami K
    Graefes Arch Clin Exp Ophthalmol; 2022 Jan; 260(1):271-280. PubMed ID: 34370066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.
    Brooks TW; Creekmore FM; Young DC; Asche CV; Oberg B; Samuelson WM
    Pharmacotherapy; 2007 May; 27(5):684-90. PubMed ID: 17461703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resting pulse rates in a glaucoma clinic: the effect of topical and systemic beta-blocker usage.
    Tattersall C; Vernon S; Singh R
    Eye (Lond); 2006 Feb; 20(2):221-5. PubMed ID: 15803169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study.
    Kalra PR; Morley C; Barnes S; Menown I; Kassianos G; Padmanabhan S; Gupta S; Lang CC
    Int J Cardiol; 2013 Sep; 167(6):2695-9. PubMed ID: 22840685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical beta-blockers are not associated with an increased risk of treatment for depression.
    Kaiserman I; Kaiserman N; Elhayany A; Vinker S
    Ophthalmology; 2006 Jul; 113(7):1077-80. PubMed ID: 16815397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why do patients fail to receive beta-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure.
    Parameswaran AC; Tang WH; Francis GS; Gupta R; Young JB
    Am Heart J; 2005 May; 149(5):921-6. PubMed ID: 15894978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can analyses of electronic patient records be independently and externally validated? Study 2--the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study.
    Springate DA; Ashcroft DM; Kontopantelis E; Doran T; Ryan R; Reeves D
    BMJ Open; 2015 Apr; 5(4):e007299. PubMed ID: 25869690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management and outcome of topical beta-blocker-induced atrioventricular block.
    Özcan KS; Güngör B; Osmonov D; Tekkeşin AI; Altay S; Ekmekçi A; Toprak E; Yildirim E; Çalik N; Alper AT; Gürkan K; Erdinler I
    Cardiovasc J Afr; 2015; 26(6):210-3. PubMed ID: 26659434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical beta-blockers and mortality.
    Müskens RP; Wolfs RC; Witteman JC; Hofman A; de Jong PT; Stricker BH; Jansonius NM
    Ophthalmology; 2008 Nov; 115(11):2037-43. PubMed ID: 18801580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do selective topical beta antagonists for glaucoma have respiratory side effects?
    Kirwan JF; Nightingale JA; Bunce C; Wormald R
    Br J Ophthalmol; 2004 Feb; 88(2):196-8. PubMed ID: 14736772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the effect on patient outcomes of appropriate and inappropriate use of beta-blockers as secondary prevention after myocardial infarction in a medicaid population.
    Fernandes AW; Madhavan SS; Amonkar MM
    Clin Ther; 2005 May; 27(5):630-45. PubMed ID: 15978313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
    Hicks BM; Murray LJ; Powe DG; Hughes CM; Cardwell CR
    Ann Oncol; 2013 Dec; 24(12):3100-6. PubMed ID: 24050955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.
    Trese MGJ; Lewis AW; Blachley TS; Stein JD; Moroi SE
    J Ocul Pharmacol Ther; 2017 Oct; 33(8):591-597. PubMed ID: 28854348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical beta blockers in asthmatic patients-is it safe?
    Kaiserman I; Fendyur A; Vinker S
    Curr Eye Res; 2009 Jul; 34(7):517-22. PubMed ID: 19899964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-Blockers for Exams Identify Students at High Risk of Psychiatric Morbidity.
    Butt JH; Dalsgaard S; Torp-Pedersen C; Køber L; Gislason GH; Kruuse C; Fosbøl EL
    J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):266-273. PubMed ID: 27782771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Combination Glaucoma Therapies on β-Blocker Exposure.
    Xu K; Campbell EL; Gill SS; Nesdole R; Campbell RJ
    J Glaucoma; 2017 Feb; 26(2):e107-e109. PubMed ID: 28059862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.
    Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF
    BMC Cardiovasc Disord; 2016 Mar; 16():60. PubMed ID: 27012911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.